EGFR and KRAS mutations in pulmonary pleomorphic carcinoma and their correlation with clinicopathologic features

about

Definitive Chemoradiotherapy for Advanced Pulmonary Sarcomatoid Carcinoma Pulmonary pleomorphic carcinoma: A case harboring EGFR mutation treated with EGFR-TKIs.

P2860

Q39555967-653A2A5A-0157-4DFC-9142-1C5726DDB6BB Q52318148-25759606-B6A1-4740-894F-FD12A88B8AB6

P2860

EGFR and KRAS mutations in pulmonary pleomorphic carcinoma and their correlation with clinicopathologic features

Item

http://www.wikidata.org/entity/Q35867291

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

EGFR and KRAS mutations in pul ...... ith clinicopathologic features

@ast

EGFR and KRAS mutations in pul ...... ith clinicopathologic features

@en

type

Item

label

EGFR and KRAS mutations in pul ...... ith clinicopathologic features

@ast

EGFR and KRAS mutations in pul ...... ith clinicopathologic features

@en

prefLabel

EGFR and KRAS mutations in pul ...... ith clinicopathologic features

@ast

EGFR and KRAS mutations in pul ...... ith clinicopathologic features

@en

P1476

EGFR and KRAS mutations in pul ...... ith clinicopathologic features

@en

P2093

Gang Chen

http://www.w3.org/2001/XMLSchema#string

Xiaoli Jia

http://www.w3.org/2001/XMLSchema#string

P2860

Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma.

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence.

Palliative chemotherapy for pulmonary pleomorphic carcinoma.

EGFR and KRAS status of primary sarcomatoid carcinomas of the lung: implications for anti-EGFR treatment of a rare lung malignancy.

Molecular profiles of EGFR, K-ras, c-met, and FGFR in pulmonary pleomorphic carcinoma, a rare lung malignancy

Mutations in the epidermal growth factor receptor gene and effects of EGFR-tyrosine kinase inhibitors on lung cancers.

Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas.

Pulmonary pleomorphic carcinoma: a clinicopathological study including EGFR mutation analysis.

EGFR and KRAS mutations in Chinese patients with adenosquamous carcinoma of the lung.

P304

22-27

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.5114/WO.2014.43491

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-03-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

280392632

http://www.w3.org/2001/XMLSchema#string

P698

26199566

http://www.w3.org/2001/XMLSchema#string

P932

4507885

http://www.w3.org/2001/XMLSchema#string

EGFR and KRAS mutations in pulmonary pleomorphic carcinoma and their correlation with clinicopathologic features

about

P2860

P2860

EGFR and KRAS mutations in pulmonary pleomorphic carcinoma and their correlation with clinicopathologic features

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P932